Results of treatment of patients with prostatic adenoma using silodosin based on an assessment of the phenotype of male sexuality
- Authors: Kogan M.I1, Kireev A.Y.1
-
Affiliations:
- Issue: No 6 (2013)
- Pages: 58-61
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/280018
- ID: 280018
Cite item
Open Access
Access granted
Abstract
The article presents the results of treatment of 40 patients with prostatic adenoma using silodosin (urorec®) at a dose of 8 mg per day. Patients were divided into three groups according to the phenotype of male sexuality based on author’s questionnaire. Evaluation of treatment results was performed after 24-week follow-up period. There was a high therapeutic effect of silodosin in all groups of patients with prostatic adenoma, but the greatest effect in terms of reduction of urination disorders and increases of maximum urinary flow rate was achieved in men with normo- and hyposexuality compared with hypersexual men. The development of ejaculation disorders during treatment with silodosin in patients with prostatic adenoma is less typical for the patients with hypersexual phenotype.
Full Text
References
- Rosen R., Altwein J., Boyle P. et al. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur. Urol. 2003; 44: 637—649.
- O’Leary M.P. Quality of life and sexuality: Methodological aspects. Eur. Urol. 2001; 40: 13—18.
- Sak S.C., Eardley I. What is the relationship between benign prostatic hyperplasia and sexual function? Sexual & Relationship Therapy 2004; 19(4): 431—443.
- Schulman C. Impact of treatment of BPH on sexuality. Prostate Canc. & Prost. Diseases. 2001; 4(1): 12—16.
- Daly M.P. Quality of life in sexually active men with symptomatic benign prostatic hyperplasia. Effects of treatment. Clin. Drug Invest. 2005; 25(4): 219—230.
- Rosen R.C., Riley A. et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997; 49: 822—830.
- Rosen R.C., Catania J. et al. Male sexual health questionnaire (MSHQ): scale development and psychometric validation. Urology. 2004; 64: 777—782.
- Коган М.И., Киреев А.Ю. Анкета интегральной оценки мужской сексуальности. Урология. 2009; 1: 46—50.
- Киреев А.Ю. О взаимосвязи мужской сексуальности с развитием и течением доброкачественной гиперплазии предстательной железы: Дисс.. канд. мед. наук. Р/Дону; 2009.
- Коган М.И., Киреев А.Ю. Сексуальность мужчины и развитие доброкачественной гиперплазии простаты. Consilium Medicum. 2009; 11(7): 75—79.
- Capitanio U., Salonia A., Briganti A. et al. Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates. Int. J Clin. Pract. 2013; 67(6): 544—551.
- Chapple C.R., Montorsi F., Tammela T.L. et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, doubleblind, placebo- and active-controlled clinical trial performed in Europe. Eur. Urol. 2011; 59: 342—552.
- Marks L.S., Gittelman M.C., Hill L.A. et al. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009; 181: 2634—2640.
- Kawabe K., Yoshida M., Homma Y. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006; 98: 1019—1024.
- Коган М.И., Киреев А.Ю. Эффективность терапии аденомы предстательной железы альфузозином в зависимости от сексуальности. Урология. 2011; 1: 28—31.
Supplementary files
